Physiologic disposition and metabolism of an anti-ulcer agent, N-(2-diisopropylaminoethyl)-N-(4,6-dimethyl-2-pyridyl)-N',N'-dimethylurea, in rats, dogs, and monkeys.

14C-N-(2-Diisopropylaminoethyl)-N-(4,6-dimethyl-2-dimethyl- 2-pyridyl)-N',N'-dimethylurea (I) was administered orally to dogs and rats and to rhesus, African green, and squirrel monkeys. Radioactivity was excreted mainly in the urine (60-76%) of all species except the rat (25%). The plasma t1/2 of I in the dog was 0.8 hr. Five urinary metabolites were identified by TLC, GLC, GS/MS, and NMR spectrometry: N,N-dimethyl-N'-(2-diisopropylaminoethyl)-N'-(4-hydroxy-methyl-6-methyl-2-pyridyl)urea (II), N,N-dimethyl-N'-(2-diisopropylaminoethyl-N'-(4-methyl-6-hydroxymethyl-2-pyridyl )urea (III), N,N-dimethyl-N'-(2-isopropylaminoethyl)-N'-(4,6-dimethyl-2-pyridyl)urea (IV), N-methyl-N'-(2-diisopropylaminoethyl)-N'-(4,6-dimethyl-2-pyridyl)urea (V), and N-(2-diisopropylaminoethyl)-N-(4,6-dimethyl-2-pyridyl)urea (VI). II was a major urinary metabolite in dog and II and IV were major metabolites in the squirrel monkey. II was present in relatively high concentrations in testes and stomach tissues of dogs, but not rats, treated with I, a finding that may be related to species differences in toxicity observed with I in these species.

Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man.

The absorption, distribution, excretion, and metabolism of 3-(5 H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine (cyclobenzaprine) were investigated in the rat, dog, rhesus monkey, and man. The drug was well absorbed in all species after oral administration. The rat eliminated the drug primarily in the feces, but urinary excretion was predominant in the dog, monkey, and man. The drug was rapidly and widely distributed into rat tissues, highest concentrations being found in the small intestine, lung, kidney, and liver. The drug was highly bound in human plasma. Extensive biliary excretion of the labeled compound was observed in the rat. Major metabolites in the rat were phenolic derivatives but in man the major metabolites were 10,11-dihydroxynortriptyline and cyclobenzaprine glucuronide. Only minor amounts of unchanged drug were present in the urine.

Plasma levels and bioavailability of cyclobenzaprine in human subjects.

Cyclobenzaprine was extensively metabolized in man, less than 1% of the dose being excreted unchanged in the urine. Comparison of areas under plasma level curves (AUC) after oral and intravenous doses suggests that the drug may be partly metabolized in the lumen or during its first passage through the gut wall and/or liver. Average plasma levels of the drug increased with increasing dosage, but the AUC increased less rapidly with increasing dose, possibly because of dose-dependent absorption.

Rapid, sensitive gas-liquid chromatographic method for determination of amitryptyline and nortriptyline in plasma using a nitrogen-sensitive detector.

A simple gas chromatographic method for determination of amitriptyline and nortriptyline in plasma using a nitrogen-sensitive detector is described. Concentrations of both drugs as low as 10 ng per ml plasma were measured. The precision and accuracy of the method are within acceptable limits.

Determination of various drugs in rodent diet mixtures.

Methods employing solvent extraction, thin-layer chromatography, gas-liquid chromatography, and UV spectrophotometry are described for the quantitative determination of halofenate, cyclobenzaprine and sulindac in rodent diet mixtures. Halofenate was hydrolyzed to its free acid derivative and converted to a methyl ester prior to assay. The drugs were shown to be stable when stored in food mixtures at room temperature for seven days. Diet mixtures containing the three drugs were demonstrated to be uniformly mixed by the procedure employed.

GLC determination of cyclobenzaprine in plasma and urine.

A GLC determination of cyclobenzaprine in human plasma and urine is described. After extraction from alkalinized samples with heptane-isopentyl alcohol (97:3), the drug and internal standard were back-extracted into 0.1 N HCl and then reextracted into ether. Use of a lower homolog of the drug as an internal standard was effective in reducing variability. Drug concentrations as low as 25 ng/ml could be assayed with high precision. Plasma levels in humans given 40 mg po or iv ranged from 5 to 51 ng/ml; little unchanged cyclobenzaprine was present in the urine. The N-desmethyl analog of the drug was detected as a metabolite in urine.

GLC analysis of lidocaine in plasma using a novel nitrogen-sensitive detector.

A simple, rapid GLC method for the determination of therapeutic levels of lidocaine in plasma or blood is described. After extraction with benzene from alkalinized plasma, the compound is analyzed by GLC using a nitrogen-sensitive detector. Quantitation is accomplished using an internal standard and a standard curve, which was linear over the 0.1-10-mug range. The limit of detection was approximately 10 ng/ml. Recovery of the parent compound was essentially quantitative. Plasma data are presented to demonstrate the utility of the method.

Plasma levels of a new pelletized form of amitriptyline for maintenance therapy.

Plasma levels of amitriptyline and nortriptyline were measured in volunteers after one week of daily dosage with either 25 mg t.i.d. of standard amitriptyline tablets or a single 75-mg capsule of a new pelletized form of amitriptyline. Concentrations of both compounds were essentially equal at the end of one week's dosage with either dosage form but were somewhat higher throughout the dosing time interval for the pelletized drug.